EMG
RNAC icon

Ellington Management Group’s Cartesian Therapeutics RNAC Stock Holding History

Ellington Management Group’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-413
Closed -$126K – 790
2018
Q1 		$126K Buy
+413
New +$118K 0.01% 773

Other funds holding RNAC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ellington Management Group's RNAC Position: Q2 2018 in Review

Ellington Management Group sold out of Cartesian Therapeutics (RNAC) in Q2 2018, closing a stake of 413 shares — an estimated $126K sold.

Ellington Management Group first reported a position in RNAC in Q1 2018 and held it in 1 quarter. The position peaked at $126K in Q1 2018. 57 funds tracked by Wall St. Rank hold RNAC as of Q2 2018.

  • Ellington Management Group reported no remaining Cartesian Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Ellington Management Group sold 413 Cartesian Therapeutics shares in Q2 2018, an estimated $126K.
  • Ellington Management Group first reported a position in Cartesian Therapeutics in Q1 2018 and held it in 1 quarter.
  • Ellington Management Group's Cartesian Therapeutics position peaked at $126K in Q1 2018.
  • 57 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2018.

Based on Ellington Management Group's 13F filing for Q2 2018, filed 14 Aug 2018.